Brian Werneburg, PhD

Reduction in Insomnia Symptoms in Patients With Postpartum Depression (PPD) Treated With the Neuroactive Steroid Brexanolone Injection

Background: PPD is one of the most common medical complications during and after pregnancy, with insomnia as a common symptom. Brexanolone injection (BRX) is a neuroactive steroid GABAA r...

C. Neill Epperson , MD;

David Rubinow , MD;

Kristina Deligiannidis , MD;

Robert Riesenberg , MD;

Kemi Bankole , PhD;

Haihong Li , PhD;

Stephen Kanes , MD, PhD;

Samantha Meltzer-Brody , MD;

Brian Werneburg , PhD;

10/08/2020

Reduction in Anxiety Symptoms in Patients With Postpartum Depression (PPD) Treated With the Neuroactive Steroid Brexanolone Injection (BRX)

Background: Anxiety is a prominent symptom and comorbidity of PPD. Post-hoc analyses of an integrated dataset from three BRX PPD trials evaluated effects of BRX on anxiety symptoms using ...

Kristina Deligiannidis , MD;

Robert Riesenberg , MD;

Kemi Bankole , PhD;

Haihong Li , PhD;

Stephen Kanes , MD, PhD;

Samantha Meltzer-Brody , MD;

Brian Werneburg , PhD;

C. Neill Epperson , MD;

David Rubinow , MD;

10/08/2020

Edinburgh Postnatal Depression Scale (EPDS) Total Score Remission and Number Needed to Treat (NNT) Outcomes in a Phase 3, Placebo-Controlled Trial of Zuranolone in Postpartum Depression (PPD)

Background: Zuranolone (SAGE-217) is an investigational, neuroactive steroid and GABAA receptor positive allosteric modulator evaluated in a Phase 3 trial in patients with PPD (NCT0297832...

Kristina Deligiannidis , MD;

Ellison Suthoff , MBA, BS ;

Stephen Kanes , MD, PhD;

Brian Werneburg , PhD;

Ming-Yi Huang , PhD;

Robert Lasser , MD, MBA;

Vijayveer Bonthapally , PhD;

Handan Gunduz-Bruce , MD, MBA;

Sarah Acaster , MSc;

Moshe Fridman , PhD;

10/08/2020

Correlation of HAMD-17 and EPDS Scores in a Phase 3 Trial of Zuranolone: An Oral GABAA Receptor Positive Allosteric Modulator in Postpartum Depression

Background: PPD is a common medical complication during and after pregnancy. Zuranolone (SAGE-217) is an investigational neuroactive steroid and GABAA receptor positive allosteric modulat...

Kristina Deligiannidis , MD;

Stephen Kanes , MD, PhD;

Ming-Yi Huang , PhD;

Robert Lasser , MD, MBA;

Handan Gunduz-Bruce , MD, MBA;

Sarah Acaster , MSc;

Moshe Fridman , PhD;

Ellison Suthoff , MBA, BS ;

Vijayveer Bonthapally , PhD;

Abdul Sankoh , PhD;

Brian Werneburg , PhD;

Sigui Li , MS;

10/08/2020

Number Needed to Treat Analysis of the SAGE-217 Phase 2 Clinical Trial Results in Major Depressive Disorder

Background: SAGE-217 is a novel, positive allosteric modulator of GABA(A) receptors under development in Major Depressive Disorder (MDD). This analysis quantified the number needed to tre...

Ken O'Day , PhD, MPA;

Vijayveer Bonthapally , PhD;

Alix Arnaud , MSc;

Ellison Suthoff , MBA, BS ;

Katie Stenson , MSc;

Brian Werneburg , PhD;

Paul Hodgkins , PhD, MSc;

Jeffrey Jonas , MD;

Kellie Meyer , PharmD, MPH;

11/22/2019